Supernus Pharmaceuticals Inc - Asset Resilience Ratio
Supernus Pharmaceuticals Inc (SUPN) has an Asset Resilience Ratio of 13.45% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Supernus Pharmaceuticals Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2025)
This chart shows how Supernus Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Supernus Pharmaceuticals Inc balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Supernus Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore SUPN long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $192.11 Million | 13.45% |
| Total Liquid Assets | $192.11 Million | 13.45% |
Asset Resilience Insights
- Moderate Liquidity: Supernus Pharmaceuticals Inc has 13.45% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Supernus Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Supernus Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for Supernus Pharmaceuticals Inc (2008–2025)
The table below shows the annual Asset Resilience Ratio data for Supernus Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.41% | $180.22 Million | $1.45 Billion | -15.68pp |
| 2024-12-31 | 28.09% | $384.28 Million | $1.37 Billion | +14.02pp |
| 2023-12-31 | 14.07% | $179.82 Million | $1.28 Billion | -7.55pp |
| 2022-12-31 | 21.63% | $368.21 Million | $1.70 Billion | +13.56pp |
| 2021-12-31 | 8.07% | $136.25 Million | $1.69 Billion | -0.84pp |
| 2020-12-31 | 8.90% | $133.89 Million | $1.50 Billion | -5.38pp |
| 2019-12-31 | 14.28% | $165.69 Million | $1.16 Billion | -2.47pp |
| 2018-12-31 | 16.75% | $163.77 Million | $977.81 Million | +7.39pp |
| 2017-12-31 | 9.36% | $39.74 Million | $424.46 Million | +1.70pp |
| 2016-12-31 | 7.66% | $23.72 Million | $309.57 Million | -7.19pp |
| 2015-12-31 | 14.86% | $28.04 Million | $188.73 Million | -12.73pp |
| 2014-12-31 | 27.59% | $37.94 Million | $137.51 Million | -16.75pp |
| 2013-12-31 | 44.34% | $49.21 Million | $111.00 Million | -6.95pp |
| 2012-12-31 | 51.29% | $48.21 Million | $93.99 Million | +50.83pp |
| 2011-12-31 | 0.46% | $245.00K | $53.73 Million | -18.61pp |
| 2010-12-31 | 19.07% | $8.96 Million | $47.01 Million | -24.88pp |
| 2009-12-31 | 43.95% | $35.12 Million | $79.90 Million | +34.23pp |
| 2008-12-31 | 9.73% | $7.50 Million | $77.13 Million | -- |
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with P… Read more